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Key points
●● Electronic nose techniques using exhaled breath components 
measurements have been able to distinguish lung cancer patients from 
both healthy individuals and patients with nonmalignant respiratory 
diseases.
●● A biomarker for lung cancer could lead to earlier diagnosis and improved 
treatment monitoring.
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E-nose techniques using exhaled breath component measurements can distinguish lung cancer 
patients from both healthy individuals and patients with nonmalignant respiratory diseases 
http://bit.ly/2QVttNr
Lung cancer is very common and the most common cause of cancer death worldwide. Despite 
recent progress in the systemic treatment of lung cancer (checkpoint inhibitors and tyrosine 
kinase inhibitors), each year, >1.5 million people die due to this disease. Most lung cancer patients 
already have advanced disease at the time of diagnosis. Computed tomography screening of high-
risk individuals can detect lung cancer at an earlier stage but at a cost of false-positive findings. 
Biomarkers could lead towards a reduction of these false-positive findings and earlier lung cancer 
diagnosis, and have the potential to improve outcomes and treatment monitoring. To date, there 
is a lack of such biomarkers for lung cancer and other thoracic malignancies, although electronic 
nose (e-nose)-derived biomarkers are of interest.
E-nose techniques using exhaled breath component measurements can detect lung cancer with 
a sensitivity ranging from 71% to 96% and specificity from 33 to 100%. In some case series, such 
results have been validated but this is mostly using internal validation and hence, more work is 
needed. Furthermore, standardised sampling and analysis methods are lacking, impeding interstudy 
comparison and clinical implementation. In this narrative review, we provide an overview of the 
currently available data on E-nose technology for lung cancer detection.
Breathe
The electronic nose: 
emerging biomarkers in 
lung cancer diagnostics
Wouter H. van Geffen 1, Kevin Lamote2,3,4,5, Adrien Costantini6, Lizza E.L. Hendriks7, 
Najib M. Rahman8,9, Torsten G. Blum10, Jan van Meerbeeck2,3,4,5
wouter.van.geffen@znb.nl
@ExtraLucht
Cite as: van Geffen WH, 
Lamote K, Costantini A, et al. 
The electronic nose: emerging 
biomarkers in lung cancer 
diagnostics. Breathe 2019; 
15: e135–e141.
e136 Breathe | December 2019 | Volume 15 | No 4
The e-nose
Lung cancer is the most common cause of cancer 
death worldwide [1]. Despite recent progress in the 
systemic treatment of lung cancer (checkpoint 
inhibitors and tyrosine kinase inhibitors), each year, 
>1.5 million people die because of lung cancer [2]. 
More than half of the lung cancer patients have 
advanced disease at the time of initial diagnosis 
[2]. Key steps to reducing lung cancer-related death 
are to diagnose lung cancer (and other thoracic 
malignancies, such as mesothelioma) earlier and 
to improve the detection of asymptomatic patients. 
Screening could be key to increasing the chance 
of cure or prolonged survival [3]. Currently, most 
screening studies and programmes incorporate 
computed tomography (CT) scans but at a cost 
of false-positive findings. The addition of a 
noninvasively obtained biomarker could provide 
much needed value to these programmes, both for 
lung cancer and mesothelioma [3, 4], by improving 
specificity and reduction of false positives or to 
provide a more personalised follow-up.
What are biomarkers?
According to the Biomarker Working Group of the 
US Food and Drug Administration and National 
Institutes of Health, a biomarker is defined as 
“a characteristic that is measured as an indicator 
of normal biological processes, pathogenic 
processes, or responses to an exposure or 
intervention, including therapeutic interventions. 
Molecular, histologic, radiographic, or physiologic 
characteristics are types of biomarkers. A biomarker 
is not an assessment of how an individual feels, 









A biomarker should fulfil criteria such as being 
detectable at a point where it would change the 
patient pathway or outcome of the disease, or allude 
to other tests in diagnostic or screening settings.
Why do we need biomarkers 
in lung cancer?
Diagnostic biomarkers
A biomarker, when available, could be useful 
in three important roles. First, it could aid in 
establishing a lung cancer diagnosis, especially 
as part of a thoracic cancer screening programme 
with a relatively high percentage of false-positive 
findings. It could also aid in selecting high-risk 
patients for a CT screening programme. In lung 
cancer, no such biomarkers have been validated 
for clinical use but in other fields, such biomarkers 
have been of interest (e.g. prostate-specific antigen 
and carcinoembryonic antigen). For lung cancer, the 
ECLS and bio-MILD trials are currently running to 
assess blood tumour markers.
Furthermore, the gold standard to diagnose 
thoracic cancers is a pathology report indicating 
malignant cells. However, quite often (e.g. in severe 
COPD patients in whom a biopsy cannot be safely 
obtained), it is not possible to gain enough tissue to 
establish a diagnosis, and the multidisciplinary team 
makes decisions based on radiology and clinical 
details. A diagnostic biomarker would be valuable 
to help support these teams in their decisions on 
probability of malignancy.
Predictive biomarkers
The second important role of a biomarker is to 
predict a future treatment response. The detection 
of epidermal growth factor receptor (EGFR) 
mutations and ALK or other driver mutations are 
regarded as successful biomarkers in non-small cell 
lung cancer (NSCLC) [6, 7]. Another biomarker used 
to predict treatment responses is the programmed 
death ligand 1 (PD-L1) tumour proportion score. 
PD-L1 is associated with checkpoint inhibitor 
efficacy in stage IV, and potentially also in stage III, 
NSCLC. In clinical trials for mesothelioma, small cell 
lung cancer and other stages of NSCLC, PD-L1 is also 
gaining more clinical attention. However, PD-L1 
assays are far from perfect, with a low sensitivity 
and specificity [2]. A significant amount of research 
activity is aimed at developing new strategies and 
biomarkers to replace or improve PD-L1. There is 
a need to improve the sensitivity and specificity of 
this biomarker, with potential for improvements 
from new or additional biomarkers.
Biomarkers for monitoring
Thirdly, a biomarker could aid in the serial 
monitoring of treatment effect, or to distinguish 
between disease progression and toxicity from 
treatments such as radiation or immunotherapy. 
Such a biomarker could be effectively used in 
parallel to information gained from CT or positron 
emission tomography scans. In lung cancer, no 
such biomarkers are available. However, this role 
for biomarkers is currently being used in other 
cancer treatments by, for example, prostate-specific 
antigen and carcinoembryonic antigen.
Ideally, a diagnostic biomarker that is designed 
to optimise efficacy and safety of low-dose CT 
screening for lung cancer and subsequent invasive 
diagnostics should have a high sensitivity and 
specificity, should be noninvasively obtained, and 
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should be easy to use and inexpensive. Exhaled 
breath analysis could fit this profile in the detection 
of thoracic malignancies. In this narrative review, we 
provide an overview of the currently available data 
on electronic nose (e-nose) as a potential diagnostic, 
predictive or monitoring biomarker for lung cancer 
treatment.
An e-nose can detect volatile organic compounds 
(VOC). It is used for both medical and nonmedical 
purposes. The e-nose for medical purposes is 
most commonly used to measure VOCs in exhaled 
breath from patients but has also been used in the 
assessment of several biological samples including 
faeces, biopsies, saliva and skin [8–10].
Volatile organic compounds
What are VOCs?
VOCs were identified in the 1970s [11]. Since then, 
breath analysis has boomed into a high-throughput 
breathomics research field with >3000 different 
VOCs discovered in human breath [12, 13]. Most 
particles in the air are biogenic and emitted through 
external processes such as the environment and 
atmospheric pollution [10]. However, due to 
metabolic processes within the human body, VOCs 
can be emitted or VOC patterns can be altered [13]. 
These processes can be physiological but can be also 
induced by or altered due to disease. Therefore, it is 
believed that these VOCs cause a specific “smell” 
or “breathprint” for different diseases. When a 
concentration of VOCs is measured directly or 
measured after being captured and stored (e.g. via 
collection bags or canisters), different breathprints 
or patterns can be detected [14].
VOCs in other diseases
VOC and breathprint detection with e-noses have 
previously been shown to be effective in respiratory 
diseases [15]. For COPD, the technique not only 
allows a COPD diagnosis but can also detect the 
origin of COPD exacerbations, and can be used 
in the differential diagnosis of COPD and asthma 
[15–17]. In asthma, it is used to detect the disease 
and to determine its phenotype. VOCs are used in 
cystic fibrosis and in the detection of tuberculosis 
[18]. Furthermore, nonrespiratory diseases can be 
detected using an e-nose (e.g.Barrett’s oesophagus 
and inflammatory bowel disease) [8, 19]. For other 
cancer types, positive e-nose studies have been 
published, including head and neck, bladder, and 
colon cancer [20].
VOCs in lung cancer
At the foundation of breath pattern research in 
cancer lies a trial by McCulloch et al. [21]. This trial 
showed that trained dogs were able to detect lung 
cancer patients in a group of volunteers including 
healthy subjects. In the 1980s, specific VOCs were 
demonstrated for the first time in patients with lung 
cancer [22]. Research then focused on identifying 
specific VOCs. Different individual VOCs assessed 
were propranolol, isoprene, acetone, pentane, 
hexanal and benzene [23]. However, at the time, 
this proved to be inadequately accurate, expensive 
and time consuming [24].
As such, interest declined. As technology 
progressed and superior sensors were 
developed, interest re-emerged, and new tests 
were performed on tissues and cell lines in the 
laboratory [9, 25]. The sensors currently being 
used focus on pattern recognition. These patterns 
need to be “learned” first by the machine using 
artificial intelligence in a manner analogous to the 
training of dogs used in the original McCulloch 
study [21]. With this principle, it has now been 
possible to differentiate lung cancer from healthy 
subjects and from COPD patients [14, 26–28]. 
Currently, issues preventing the technique 
from being widespread in clinical practice 
include stability of the VOCs, and stability and 
interchangeability of the devices [29]. If these 
issues can be resolved, we anticipate that e-noses 
may find their way to routine practice.
Progress has also been made in mesothelioma. 
The first tests were published in 2012 [30, 31], 
showing that molecular pattern recognition of 
exhaled breath could distinguish mesothelioma 
patients from healthy controls. More recently, this 
was confirmed by a study combining breath analysis 
by gas chromatography–mass spectrometry and an 
e-nose [32, 33].
E-noses
Different technological principles are used in 
different e-noses. Differences between e-noses 
occur at many levels, the most obvious one being 
the air sampling technique. Some noses require a 
holding canister while others use air inside a sample 
balloon. Almost every system needs a contained 
environment at the moment of sampling and 
measurement to prevent contamination, especially 
to reduce the influence of disinfectants or cigarette 
smoke [24, 34].
Additional differences occur at the level of 
methodical principles. Some older e-noses 
measured individual VOCs contrasted by other, 
more modern noses that assess patterns, the latter 
requiring training in test sets and validation in an 
independent set before rendering useful results. 
Most of the pattern recognition noses are used in 
combination with artificial intelligence [7].
The most important difference, however, lays 
in the different type of sensors used inside the 
technology. The most commonly used techniques 
are gas chromatography, spectrometry, colorimetry, 
surface acoustic waves and conductometry [34].
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Gas chromatography
This technique allows the separation of different 
types of molecules. The air sample is combined with 
a carrier gas and then moves against a stationary 
component with a reaction as result. Different 
substances provide a different responses, with simple 
chromatography as an obvious example [34, 35].
Spectrometry
Spectrometers are most often combined with gas 
chromatography. These are used as devices for the 
identification of specific chemicals. After ionisation 
of the compounds, the ions from the molecules 
are separated according to mass-to-charge ratio. 
This separation normally occurs in a vacuum with 
a magnetic field. The technique is cumbersome, 
expensive and difficult to transport, and to date, no 
point-of-care system with this technique is widely 
used [34, 36].
Colorimetry
Colorimetric devices work with sensors with 
chemically responsive dyes. These dyes can be 
adapted based on the targeted VOC. Multiple dyes 
can be used in one sensor, allowing patterns of VOCs 
to be detected [36].
Surface acoustic wave
Acoustic sensors work by exposing their sensors to 
gases. The gases then change an already emitted 
acoustic wave due to reactions with the sensor 
surface. These waves are then analysed for VOC or 
pattern identification [34].
Conductometry
This technique works with sensors (e.g. metal 
oxide or polymeric sensors) that consist of different 
metals that allow for various interactions with 
volatile compounds. Exhaled air is guided over these 
sensors, allowing redox reactions to occur, resulting 
in conductivity changes of the sensors [16, 34, 37].
Current level of evidence 
and current limitations
Diagnostic e-nose biomarkers
When we assess the potential roles of biomarkers 
in thoracic disease, most VOC-based research 
has been dedicated to the detection of cancer. 
To date, e-noses have been able to detect cancer in 
different settings and have been tested in vitro. They 
can distinguish lung cancer patients from healthy 
patients, both in volunteers and in those suspected 
of having cancer [38]. Such studies most commonly 
assess VOCs emitted by cells in a laboratory setting, 
with some in vivo studies, but mostly in pilot form.
These studies have demonstrated the detection 
of lung cancer with a sensitivity ranging from 
71% to 96% and specificity from 33 to 100% 
(table 1). Several attempts have been made to 
validate these results but have mostly only been 
conducted using internal validation. There is a lack 
of standardised sampling and analysis method, 
impeding interstudy comparison and clinical 
implementation [29, 43, 44].
Predictive e-nose biomarkers
For the role of a biomarker in predicting future 
treatment responses, research is very limited. In 
a small pilot study, the e-nose has been able to 
differentiate between EGFR-mutated and wild-type 
EGFR NSCLC; however, more research to assess 
this is necessary [45]. A recently published study 
tested an e-nose for the prediction of response to 
anti-PD-1 therapy in patients with NSCLC with the 
area under the curve confirmed in the validation 
set to be 0.85 [46].
Monitoring e-nose biomarkers
For this specific role, at this stage, we have found 
no published data. However, efforts to study this 
specific role for the e-nose are being developed.
Self-evaluation questions
1. Which of the following statements regarding lung cancer screening is 
true?
a. PD-L1 is a suitable biomarker.
b. Liquid biopsy yields a suitable biomarker.
c. Electronic nose (e-nose) analysis yields a suitable biomarker.
d. No suitable biomarker is available.
2. Which of the following statements regarding volatile organic 
compounds (VOCs) is true?
a. They can only be sniffed out by dogs.
b. They can only be sniffed out only by e-noses.
c. They can be sniffed out by both dogs and e-noses.
d. They cannot be sniffed out.
3. When was the idea of measuring VOCs to detect lung cancer first 
published?
a. In the 1980s
b. Between 2010 and 2019
c. Between 2000 and 2010
d. In this paper
4. In lung cancer patients, the e-nose:
a. is useless.
b. can be used to differ between healthy subjects and lung cancer 
patients.
c. can replace PD-L1 detection.
d. can replace computed tomography of the chest.
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Summary
E-nose techniques using exhaled breath component 
measurements can detect lung cancer with a 
sensitivity ranging from 71% to 96% and specificity 
from 33 to 100%. However, moment standardised 
sampling and analysis methods are lacking, 
impeding interstudy comparison and clinical 
implementation.
Future research
Future directions of research in this field include the 
use of artificial intelligence to enhance specificity 
and sensitivity in lung cancer detection. Large scale 
validation studies with different devices in different 
locations according to the advised technical 
standards are now required to move the field 
forward [5, 43, 44, 47]. Such new studies could test 
whether the e-nose could be useful as biomarker for 
population screenings purposes. A trial with such 
a design is currently enrolling (www.clinicaltrials.
gov identifier NCT02612532), aiming to include 
4000 subjects. Other areas for future research 
include the assessment of the e-nose in prediction 
of treatment response, treatment monitoring, or 
the differentiation of treatment complications (e.g. 
pneumonitis) from disease progression [46, 48]. 
The potential to combine different VOC and 
radiological or pathological markers to reduce the 
assumptive risks associated with each one and to 
enhance their performance is a field that is fertile 
for future research [49].
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Table 1 The most important published studies assessing the efficacy of the e-nose for lung cancer
First author [ref.] Year Lung cancer patients 
included/total 
study participants
Type of nose Result
Philips [36] 2008 95/180 Gas chromatography and mass 
spectroscopy
Sensitivity: 74%; specificity: 71%
Bajtarevic [35] 2009 220/661 Gas chromatography and mass 
spectrometry
Sensitivity: 71; specificity: 100%
Dragonieri [39] 2009 10/30 Cyranose Cross-validation value of 90% correct; 
sensitivity and specificity not reported
D’Amico [40] 2010 28/148 Gas chromatography and mass 
spectroscopy
Sensitivity: 85%; specificity: 100%
Gasparri [41] 2016 70/146 Gas sensor array composed of 
quartz microbalances
Sensitivity: 81%; specificity: 91%
Rocco [12] 2016 23/100 Pneumopipe Sensitivity: 86%; specificity: 95%
De Vries [15] 2018 35/604 Spironose Sensitivity 80%; specificity 90%
Huang [28] 2018 56/244 Cyranose Multiple models
Support vector machine
Sensitivity: 83%; specificity: 86%
Tirzïte [26] 2018 252/475 Cyranose Two different models for smokers 
(sensitivity: 96%; specificity: 92%) 
and nonsmokers (sensitivity: 96%; 
specificity: 91%)
Kort [27] 2018 144/290 Aeonose Multiple models used in the same 
population
Sensitivity: 94%; specificity: 33% (for 
the NSCLC model)
Van de Goor [42] 2018 52/144 Aeonose Sensitivity: 83%; specificity: 84%
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